세계 수술 후 통증 관리 시장 : 제품 유형별, 최종 사용자별, 지역별 - 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently published an in-depth analysis of the global Postoperative Pain Management Market, offering a comprehensive overview of key market dynamics, growth drivers, challenges, and emerging trends. This report provides valuable insights into the Postoperative Pain Management Market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2024 to 2031.

The global postoperative pain management market was valued at US$ 41.0 billion in 2024. It's projected to grow at a 5% CAGR, reaching US$ 57.8 billion by 2031.

Key Insights:

• Postoperative Pain Management Market Size (2024) - US$ 41.0 Bn
• Projected Market Value (2031) - US$ 57.8 Bn
• Global Market Growth Rate (2024-2031) - 5% CAGR

Postoperative Pain Management Market - Report Scope:

Effective postoperative pain management is critical for patient recovery and satisfaction. This report delves into the various strategies, technologies, and pharmaceuticals driving advancements in postoperative pain management globally. It encompasses a wide array of factors impacting the market, from regulatory landscape to technological innovations and patient demographics.

Market Growth Drivers:

The Postoperative Pain Management Market is fueled by several factors. A significant driver is the rising number of surgical procedures worldwide, coupled with increasing awareness regarding the importance of efficient pain management for enhanced patient outcomes. Additionally, advancements in pharmaceuticals, such as the development of novel analgesics and sustained-release formulations, contribute to market growth. Moreover, the growing adoption of minimally invasive surgical techniques necessitates tailored pain management solutions, further boosting market demand.

Market Restraints:

Challenges exist within the Postoperative Pain Management Market. These include regulatory hurdles surrounding the approval and commercialization of new pain management drugs, as well as concerns regarding opioid misuse and addiction. Moreover, economic constraints and limited access to advanced pain management techniques in certain regions hinder market expansion. Additionally, the lack of standardized protocols for pain assessment and management poses challenges for healthcare providers, impacting market growth.

Market Opportunities:

The Postoperative Pain Management Market presents ample opportunities for innovation and expansion. Collaborative efforts between pharmaceutical companies and research institutions can lead to the development of safer and more effective pain management therapies. Furthermore, the integration of digital health solutions, such as mobile applications for real-time pain monitoring and telemedicine for remote consultations, can revolutionize postoperative care delivery. Moreover, the growing focus on personalized medicine opens avenues for precision pain management approaches tailored to individual patient needs.

Key Questions Answered in the Report:

• What are the primary drivers shaping the growth of the Postoperative Pain Management Market?
• Which pharmaceuticals and technologies hold the greatest potential for improving postoperative pain management outcomes?
• How are regulatory frameworks influencing the development and commercialization of pain management therapies?
• Who are the key players leading innovation in the global Postoperative Pain Management Market?
• What emerging trends and future prospects are anticipated in the field of postoperative pain management?

Competitive Intelligence and Business Strategy:

In the competitive landscape of postoperative pain management, major suppliers are strategically engaging in collaborations and acquisitions with various pharmaceutical companies to innovate and expand their product lines. For instance, in May 2020, Zyla Life Sciences acquired Assertio Therapeutics, Inc., resulting in the formation of a robust commercial pharmaceutical entity. This acquisition facilitated the expansion of their product portfolio, particularly in the areas of neurology, inflammation, and pain management products, reinforcing their position in the market and enhancing their ability to address the evolving needs of patients and healthcare providers.

Key Companies Profiled:

• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Allergan plc
• Mylan N.V
• Pfizer Inc.
• Purdue Pharma L.P
• Janssen Pharmaceuticals, Inc.
• Endo International plc
• Pacira Pharmaceuticals Inc.
• Egalet Corporation
• GlaxoSmithKline Plc.

Postoperative Pain Management Market Segmentation:

Postoperative Pain Management Market by Drug Class:

• Opioids
• NSAIDs
• Local Anesthetic
• Acetaminophen

Postoperative Pain Management Market by Route of Administration:

• Injectable Postoperative Pain Management
• Oral Postoperative Pain Management
• Topical Postoperative Pain Management
• Transdermal Postoperative Pain Management
• Others

Postoperative Pain Management Market by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Clinics
• Others

Postoperative Pain Management Market by Region:

• North America Postoperative Pain Management Market
• Latin America Postoperative Pain Management Market
• Europe Postoperative Pain Management Market
• East Asia Postoperative Pain Management Market
• South Asia Postoperative Pain Management Market
• Oceania Postoperative Pain Management Market
• The Middle East and Africa (MEA) Postoperative Pain Management Market

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Key Development Trends

4. Market Background

• 4.1. Macro-Economic Factors
  • 4.1.1. Global GDP Growth Outlook
  • 4.1.2. Global Healthcare Expenditure Outlook
  • 4.1.3. Emerging Countries Healthcare and Development Outlook
• 4.2. Forecast Factors - Relevance & Impact
  • 4.2.1. Average Annual Spending on Pain Management Drugs
  • 4.2.2. Average Healthcare Expenditure
  • 4.2.3. Increasing Prevalence of Chronic and Acute Diseases
  • 4.2.4. Growing Number of Patients undergoing Surgical Interventions
  • 4.2.5. Rising Number of Population Suffering from End-stage Diseases
  • 4.2.6. Per Capita Pharmaceutical Expenditure
  • 4.2.7. Awareness for Pain Management Drugs
  • 4.2.8. Favourable Reimbursement Policies
  • 4.2.9. Regulatory Control over Prescription
  • 4.2.10. Popularity of Generic Products
  • 4.2.11. Patent Expiration of Novel Pain Management Drugs (Opioids)
  • 4.2.12. Introduction of Novel Abuse-deterrent Pain Management Drugs
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Trends
  • 4.3.4. Opportunity Analysis

5. Market Context

• 5.1. Promotional and Marketing Strategies, By Key Services Providers
• 5.2. Description of Industry Evolution and Main developments
• 5.3. Regulatory Scenario
• 5.4. Technological Evaluation and Advancements
• 5.5. Key Industry Events
• 5.6. Porter's Five Force Analysis

6. COVID19 Crisis Analysis

• 6.1. Current COVID19 Statistics and Probable Future Impact
• 6.2. Current GDP Projection and Probable Impact
• 6.3. Current Economic Projection as compared to 2008 financial analysis
• 6.4. COVID19 and Impact Analysis
  • 6.4.1. Revenue By Drug Class
  • 6.4.2. Revenue By Route of Administration
  • 6.4.3. Revenue By Distribution Channel
  • 6.4.4. Revenue By Country
• 6.5. 2022 Market Scenario
• 6.6. Quarter by Quarter Forecast
• 6.7. Projected recovery Quarter
• 6.8. Recovery Scenario- Short term, Midterm and Long Term Impact

7. Global Postoperative Pain Management Market Value (US$ Mn) Analysis 2019-2023 and Forecast, 2022-2031

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2031
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031, By Drug Class

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2024-2031
  • 8.3.1. Opioids
  • 8.3.2. NSAIDS
  • 8.3.3. Local Anaesthetics
  • 8.3.4. Acetaminophen
• 8.4. Market Attractiveness Analysis By Drug Class

9. Global Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031, By Route of Administration

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2031
  • 9.3.1. Injectable
  • 9.3.2. Oral
  • 9.3.3. Topical
  • 9.3.4. Transdermal
  • 9.3.5. Others
• 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Drug Store
  • 10.3.4. Clinics
  • 10.3.5. Others
• 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031, by Region

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. South Asia
  • 11.3.5. East Asia
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa (MEA)
• 11.4. Market Attractiveness Analysis By Region

12. North America Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Drug Class
  • 12.3.3. By Route of Administration
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
• 12.5. Key Market Participants - Intensity Mapping
• 12.6. Drivers and Restraints - Impact Analysis

13. Latin America Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 13.3.1. By Country
    • 13.3.1.1. Brazil
    • 13.3.1.2. Mexico
    • 13.3.1.3. Argentina
    • 13.3.1.4. Rest of Latin America
  • 13.3.2. By Drug Class
  • 13.3.3. By Route of Administration
  • 13.3.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
• 13.5. Key Market Participants - Intensity Mapping
• 13.6. Drivers and Restraints - Impact Analysis

14. Europe Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 14.3.1. By Country
    • 14.3.1.1. U.K.
    • 14.3.1.2. Germany
    • 14.3.1.3. France
    • 14.3.1.4. Italy
    • 14.3.1.5. Spain
    • 14.3.1.6. Russia
    • 14.3.1.7. BENELUX
    • 14.3.1.8. Rest of Europe
  • 14.3.2. By Drug Class
  • 14.3.3. By Route of Administration
  • 14.3.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
• 14.5. Key Market Participants - Intensity Mapping
• 14.6. Drivers and Restraints - Impact Analysis

15. South Asia Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 15.3.1. By Country
    • 15.3.1.1. India
    • 15.3.1.2. Thailand
    • 15.3.1.3. Indonesia
    • 15.3.1.4. Malaysia
    • 15.3.1.5. Rest of South Asia
  • 15.3.2. By Drug Class
  • 15.3.3. By Route of Administration
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
• 15.5. Key Market Participants - Intensity Mapping
• 15.6. Drivers and Restraints - Impact Analysis

16. East Asia Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 16.3.1. By Country
    • 16.3.1.1. China
    • 16.3.1.2. Japan
    • 16.3.1.3. South Korea
    • 16.3.1.4. Rest of East Asia
  • 16.3.2. By Drug Class
  • 16.3.3. By Route of Administration
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
• 16.5. Key Market Participants - Intensity Mapping
• 16.6. Drivers and Restraints - Impact Analysis

17. Oceania Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 17.3.1. By Country
    • 17.3.1.1. Australia
    • 17.3.1.2. New Zealand
  • 17.3.2. By Drug Class
  • 17.3.3. By Route of Administration
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Postoperative Pain Management Market Analysis 2019-2023 and Forecast 2022-2031

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
  • 18.3.1. By Country
    • 18.3.1.1. GCC Countries
    • 18.3.1.2. Turkey
    • 18.3.1.3. Northern Africa
    • 18.3.1.4. South Africa
    • 18.3.1.5. Rest of Middle East and Africa
  • 18.3.2. By Drug Class
  • 18.3.3. By Route of Administration
  • 18.3.4. By Distribution Channel
• 18.4. Market Attractiveness Analysis
• 18.5. Key Market Participants - Intensity Mapping
• 18.6. Drivers and Restraints - Impact Analysis

19. Emerging Countries Postoperative Pain Management Market Analysis 2022 & 2031

• 19.1. Introduction
  • 19.1.1. Market Value Proportion Analysis, By Key Countries
  • 19.1.2. Global Vs. Country Growth Comparison
• 19.2. U.S. Postoperative Pain Management Market Analysis
  • 19.2.1. By Drug Class
  • 19.2.2. By Route of Administration
  • 19.2.3. By Distribution Channel
• 19.3. Canada Postoperative Pain Management Market Analysis
  • 19.3.1. By Drug Class
  • 19.3.2. By Route of Administration
  • 19.3.3. By Distribution Channel
• 19.4. Mexico Postoperative Pain Management Market Analysis
  • 19.4.1. By Drug Class
  • 19.4.2. By Route of Administration
  • 19.4.3. By Distribution Channel
• 19.5. Brazil Postoperative Pain Management Market Analysis
  • 19.5.1. By Drug Class
  • 19.5.2. By Route of Administration
  • 19.5.3. By Distribution Channel
• 19.6. U.K. Postoperative Pain Management Market Analysis
  • 19.6.1. By Drug Class
  • 19.6.2. By Route of Administration
  • 19.6.3. By Distribution Channel
• 19.7. Germany Postoperative Pain Management Market Analysis
  • 19.7.1. By Drug Class
  • 19.7.2. By Route of Administration
  • 19.7.3. By Distribution Channel
• 19.8. France Postoperative Pain Management Market Analysis
  • 19.8.1. By Drug Class
  • 19.8.2. By Route of Administration
  • 19.8.3. By Distribution Channel
• 19.9. Italy Postoperative Pain Management Market Analysis
  • 19.9.1. By Drug Class
  • 19.9.2. By Route of Administration
  • 19.9.3. By Distribution Channel
• 19.10. Spain Postoperative Pain Management Market Analysis
  • 19.10.1. By Drug Class
  • 19.10.2. By Route of Administration
  • 19.10.3. By Distribution Channel
• 19.11. BENELUX Postoperative Pain Management Market Analysis
  • 19.11.1. By Drug Class
  • 19.11.2. By Route of Administration
  • 19.11.3. By Distribution Channel
• 19.12. Russia Postoperative Pain Management Market Analysis
  • 19.12.1. By Drug Class
  • 19.12.2. By Route of Administration
  • 19.12.3. By Distribution Channel
• 19.13. China Postoperative Pain Management Market Analysis
  • 19.13.1. By Drug Class
  • 19.13.2. By Route of Administration
  • 19.13.3. By Distribution Channel
• 19.14. Japan Postoperative Pain Management Market Analysis
  • 19.14.1. By Drug Class
  • 19.14.2. By Route of Administration
  • 19.14.3. By Distribution Channel
• 19.15. South Korea Postoperative Pain Management Market Analysis
  • 19.15.1. By Drug Class
  • 19.15.2. By Route of Administration
  • 19.15.3. By Distribution Channel
• 19.16. India Postoperative Pain Management Market Analysis
  • 19.16.1. By Drug Class
  • 19.16.2. By Route of Administration
  • 19.16.3. By Distribution Channel
• 19.17. ASEAN Postoperative Pain Management Market Analysis
  • 19.17.1. By Drug Class
  • 19.17.2. By Route of Administration
  • 19.17.3. By Distribution Channel
• 19.18. Australia Postoperative Pain Management Market Analysis
  • 19.18.1. By Drug Class
  • 19.18.2. By Route of Administration
  • 19.18.3. By Distribution Channel
• 19.19. New Zealand Postoperative Pain Management Market Analysis
  • 19.19.1. By Drug Class
  • 19.19.2. By Route of Administration
  • 19.19.3. By Distribution Channel
• 19.20. GCC Countries Postoperative Pain Management Market Analysis
  • 19.20.1. By Drug Class
  • 19.20.2. By Route of Administration
  • 19.20.3. By Distribution Channel
• 19.21. Turkey Postoperative Pain Management Market Analysis
  • 19.21.1. By Drug Class
  • 19.21.2. By Route of Administration
  • 19.21.3. By Distribution Channel
• 19.22. South Africa Postoperative Pain Management Market Analysis
  • 19.22.1. By Drug Class
  • 19.22.2. By Route of Administration
  • 19.22.3. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Concentration
• 20.4. Market Presence Analysis
  • 20.4.1. By Regional footprint of Players
  • 20.4.2. Product foot print by Players
  • 20.4.3. Channel Foot Print by Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. Teva Pharmaceutical Industries Ltd.
    • 21.3.1.1. Overview
    • 21.3.1.2. Services Portfolio
    • 21.3.1.3. Analyst Commentary
    • 21.3.1.4. Key Financials
    • 21.3.1.5. Recent Developments
    • 21.3.1.6. Sales Footprint
    • 21.3.1.7. Strategy Overview
      • 21.3.1.7.1. Marketing Strategy
      • 21.3.1.7.2. Services Strategy
      • 21.3.1.7.3. Channel Strategy
  • 21.3.2. Novartis AG
    • 21.3.2.1. Overview
    • 21.3.2.2. Services Portfolio
    • 21.3.2.3. Analyst Commentary
    • 21.3.2.4. Key Financials
    • 21.3.2.5. Recent Developments
    • 21.3.2.6. Sales Footprint
    • 21.3.2.7. Strategy Overview
      • 21.3.2.7.1. Marketing Strategy
      • 21.3.2.7.2. Services Strategy
      • 21.3.2.7.3. Channel Strategy
  • 21.3.3. Allergan plc
    • 21.3.3.1. Overview
    • 21.3.3.2. Services Portfolio
    • 21.3.3.3. Analyst Commentary
    • 21.3.3.4. Key Financials
    • 21.3.3.5. Recent Developments
    • 21.3.3.6. Sales Footprint
    • 21.3.3.7. Strategy Overview
      • 21.3.3.7.1. Marketing Strategy
      • 21.3.3.7.2. Services Strategy
      • 21.3.3.7.3. Channel Strategy
  • 21.3.4. Mylan N.V
    • 21.3.4.1. Overview
    • 21.3.4.2. Services Portfolio
    • 21.3.4.3. Analyst Commentary
    • 21.3.4.4. Key Financials
    • 21.3.4.5. Recent Developments
    • 21.3.4.6. Sales Footprint
    • 21.3.4.7. Strategy Overview
      • 21.3.4.7.1. Marketing Strategy
      • 21.3.4.7.2. Services Strategy
      • 21.3.4.7.3. Channel Strategy
  • 21.3.5. Pfizer Inc.
    • 21.3.5.1. Overview
    • 21.3.5.2. Services Portfolio
    • 21.3.5.3. Analyst Commentary
    • 21.3.5.4. Key Financials
    • 21.3.5.5. Recent Developments
    • 21.3.5.6. Sales Footprint
    • 21.3.5.7. Strategy Overview
      • 21.3.5.7.1. Marketing Strategy
      • 21.3.5.7.2. Services Strategy
      • 21.3.5.7.3. Channel Strategy
  • 21.3.6. Purdue Pharma L.P
    • 21.3.6.1. Overview
    • 21.3.6.2. Services Portfolio
    • 21.3.6.3. Analyst Commentary
    • 21.3.6.4. Key Financials
    • 21.3.6.5. Recent Developments
    • 21.3.6.6. Sales Footprint
    • 21.3.6.7. Strategy Overview
      • 21.3.6.7.1. Marketing Strategy
      • 21.3.6.7.2. Services Strategy
      • 21.3.6.7.3. Channel Strategy
  • 21.3.7. Janssen Pharmaceuticals, Inc.
    • 21.3.7.1. Overview
    • 21.3.7.2. Services Portfolio
    • 21.3.7.3. Analyst Commentary
    • 21.3.7.4. Key Financials
    • 21.3.7.5. Recent Developments
    • 21.3.7.6. Sales Footprint
    • 21.3.7.7. Strategy Overview
      • 21.3.7.7.1. Marketing Strategy
      • 21.3.7.7.2. Services Strategy
      • 21.3.7.7.3. Channel Strategy
  • 21.3.8. Endo International plc
    • 21.3.8.1. Overview
    • 21.3.8.2. Services Portfolio
    • 21.3.8.3. Analyst Commentary
    • 21.3.8.4. Key Financials
    • 21.3.8.5. Recent Developments
    • 21.3.8.6. Sales Footprint
    • 21.3.8.7. Strategy Overview
      • 21.3.8.7.1. Marketing Strategy
      • 21.3.8.7.2. Services Strategy
      • 21.3.8.7.3. Channel Strategy
  • 21.3.9. Pacira Pharmaceuticals Inc.
    • 21.3.9.1. Overview
    • 21.3.9.2. Services Portfolio
    • 21.3.9.3. Analyst Commentary
    • 21.3.9.4. Key Financials
    • 21.3.9.5. Recent Developments
    • 21.3.9.6. Sales Footprint
    • 21.3.9.7. Strategy Overview
      • 21.3.9.7.1. Marketing Strategy
      • 21.3.9.7.2. Services Strategy
      • 21.3.9.7.3. Channel Strategy
  • 21.3.10. Egalet Corporation
    • 21.3.10.1. Overview
    • 21.3.10.2. Services Portfolio
    • 21.3.10.3. Analyst Commentary
    • 21.3.10.4. Key Financials
    • 21.3.10.5. Recent Developments
    • 21.3.10.6. Sales Footprint
    • 21.3.10.7. Strategy Overview
      • 21.3.10.7.1. Marketing Strategy
      • 21.3.10.7.2. Services Strategy
      • 21.3.10.7.3. Channel Strategy
  • 21.3.11. GlaxoSmithKline Plc.
    • 21.3.11.1. Overview
    • 21.3.11.2. Services Portfolio
    • 21.3.11.3. Analyst Commentary
    • 21.3.11.4. Key Financials
    • 21.3.11.5. Recent Developments
    • 21.3.11.6. Sales Footprint
    • 21.3.11.7. Strategy Overview
      • 21.3.11.7.1. Marketing Strategy
      • 21.3.11.7.2. Services Strategy
      • 21.3.11.7.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology